A phase 3 trial of bevacizumab in ovarian cancer.
By T. Perren, A. Swart, J. Pfisterer, Jonathan A. Ledermann, E. Pujade-Lauraine, G. Kristensen, M. Carey, P. Beale, A. Cervantes, C. Kurzeder and 16 more. New England Journal of Medicine, 2011
2,021 citations recorded by the source corpus.
Subfields: Molecular Biology, Reproductive Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/0e3556efd3e465bf96e48c79d0a20d0891f47d25
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Reproductive Medicine
Citations in the corpus
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “4 [117]”
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial (2015, background): “928 www.thelancet.com/oncology Vol 16 August 2015 Lancet Oncol 2015; 16: 928–36 Published Online June 24, 2015 http://dx.doi.org/10.1016/ S1470-2045(15)00086-8 See Comment page 876 *Additional ICON7 trial investigators who participated in this trial are listed in the appendix Princess Margaret Cance”
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, background): “Metastatic 1st line Paclitaxel/carboplatin ± bevacizumab ICON-7 [36] Improvement in PFS, OS NA Paclitaxel/carboplatin ± bevacizumab GOG218 [37] Improvement in PFS, OS confounded by cross-over Metastatic 2nd line Gemcitabine/carboplatin ± bevacizumab OCEANS [38] Improvement in PFS but not OS”
- Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. (2018, background): “[119] Ovarian cancer (70% stage IIIC or IV) 1528 Group 2 Chemotherapy + Bevacizumab Group 2 PFS: 24.”
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer (2019, neutral): “Abdominal pain 118 (32) 14 (4) 113 (30) 13 (3) 127 (34) 17 (5)”
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Two large randomised clinical trials (GOG-218 and ICON-7) have assessed the addition of bevacizumab to the combination of paclitaxel and carboplatin in front-line therapy [46, 47].”